atezolizumab,cabozantinib
roche,exelixis
['nsclc', 'cosmic-021', 'sclc']
. stopped by to discuss the cosmic-021 study for patients with advanced #nsclc previously treated with immune checkpoint inhibitors. #asco22 interested in discussing you presentation? message us to learn how you can be interviewed. 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.